T. McNamara

发表

Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.

M. Abelson, Jon I Williams, G. Torkildsen, 2009, Clinical therapeutics.

Non-clinical pharmacology, pharmacokinetics, and safety findings for the antihistamine bepotastine besilate

A. Salapatek, Jon I Williams, Jon I. Williams, 2010, Current medical research and opinion.

Multicenter clinical evaluation of bepotastine besilate ophthalmic solutions 1.0% and 1.5% to treat allergic conjunctivitis.

M. Abelson, Jon I Williams, P. Gomes, 2010, American journal of ophthalmology.

Ocular pharmacokinetics of a single dose of bromfenac sodium ophthalmic solution 0.1% in human aqueous humor.

K. Miyake, T. Ogawa, T. Tajika, 2008, Journal of Ocular Pharmacology and Therapeutics.

24-hour evaluation of the ocular distribution of (14)C-labeled bromfenac following topical instillation into the eyes of New Zealand White rabbits.

Clara K Song, G. Baklayan, C. Song, 2008, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

Bepotastine Besilate Ophthalmic Solution 1.5% for Up to 8 Hours Following Dosing Reduces Total Non-Ocular Symptoms, Rhinorrhea, and Tearing in a Multi-Site Clinical Model of Allergic Conjunctivitis

E. Meier, E. McLaurin, P. Gomes, 2009 .

Bepotastine Besilate Ophthalmic Solution 1.5% Reduces Ocular Itching in a Clinical Model of Allergic Conjunctivitis

G. Torkildsen, P. Gomes, J. Gow, 2009 .

Bepotastine Besilate Ophthalmic Solution 1.0% Provides Rapid Relief of Rhinorrhea, Total Non-Ocular Symptoms, Tearing, and Ciliary and Episcleral Hyperemia Following Dosing in a Multi-Site Clinical Model of Allergic Conjunctivitis

E. Meier, E. McLaurin, P. Gomes, 2009 .

Ascites ‐ an Unusual Association with Pelvic Inflammatory Disease

M. Gregora, T. McNamara, 1997, The Australian & New Zealand journal of obstetrics & gynaecology.

Bepotastine besilate ophthalmic solution for the relief of nonocular symptoms provoked by conjunctival allergen challenge.

M. Abelson, Jon I Williams, G. Torkildsen, 2010, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Prolonged effectiveness of bepotastine besilate ophthalmic solution for the treatment of ocular symptoms of allergic conjunctivitis.

Kathryn S. Kennedy, M. Abelson, Jon I Williams, 2011, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

Safety and efficacy of bromfenac ophthalmic solution (Bromday) dosed once daily for postoperative ocular inflammation and pain.

B. Henderson, J. Gayton, J. Gow, 2011, Ophthalmology.

Predicting response of vitreous hemorrhage after intravitreous injection of highly purified ovine hyaluronidase (Vitrase) in patients with diabetes.

A. Bhavsar, Ronald K. Pearson, A. Hochberg, 2008, Investigative ophthalmology & visual science.

Once daily dosing of bromfenac ophthalmic solution 0.09% for postoperative ocular inflammation and pain

J. Peace, E. Sadri, S. Silverstein, 2011, Current medical research and opinion.

Efficacy of bepotastine besilate ophthalmic solution 1.5% for seasonal allergic conjunctivitis: a randomized, placebo-controlled, natural exposure, clinical trial.

W. Carr, P. Ratner, Jon I Williams, 2013, Allergy and asthma proceedings.

Pharmacokinetic Profile of Topically Applied Bromfenac Sodium Ophthalmic Solution 0.1% in Subjects Undergoing Cataract Surgery

K. Miyake, T. Ogawa, J. Gow, 2006 .

Concentrations of Radioactivity in Ocular Tissues Following a Single Topical Ocular Dose of 14C–Bromfenac Ophthalmic Solution (XibromTM)

G. Baklayan, J. Gow, T. McNamara, 2006 .